Carregant...
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR s...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5927525/ https://ncbi.nlm.nih.gov/pubmed/29721373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1423167 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|